Business Context and Reporting Period
This Form 8-K was filed by Progyny, Inc. on February 12, 2020, reporting events occurring on February 11, 2020. The company is an emerging growth company incorporated in Delaware with its principal executive offices in New York, New York. Its common stock trades on The Nasdaq Stock Market LLC under the symbol PGNY.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
The material change reported is the departure of an executive officer:
- Resignation: Karin Ajmani resigned as Chief of Strategic Development.
- Effective Date: The resignation is effective as of March 2, 2020.
- Replacement: The Company does not intend to replace her role.
- Transition: Ms. Ajmani will serve in a transition role through the effective date.
- Succession: Responsibilities will be assumed by Lisa Greenbaum, Chief Client Officer.
Management Commentary and Risks
Management commentary highlights the background of the successor, Lisa Greenbaum, who joined Progyny in June 2019. She is responsible for revenue generation and business development, leading sales and account management organizations. She possesses over 25 years of healthcare experience, including senior roles at Health Stream, Merck, Procter and Gamble, and WebMD. The filing does not disclose specific risks, contingencies, or unusual items beyond the standard personnel transition.
Key Facts for Investor Verification
- Confirm the effective date of Karin Ajmani's departure (March 2, 2020).
- Verify that the Chief of Strategic Development role will remain vacant.
- Assess the impact of consolidating strategic development duties under Lisa Greenbaum, the Chief Client Officer.
- Note that no financial data is included in this specific filing.